Synthetic pDNA Vaccines for Specialized Environments

Publication ID: 24-11857621_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Synthetic pDNA Vaccines for Specialized Environments,” Published Technical Disclosure No. 24-11857621_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857621_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,621.

Summary of the Inventive Concept

This inventive concept adapts synthetic pDNA vaccines against COVID-19 for specific, high-need environments, including high-security facilities, disaster relief, extreme weather conditions, areas with limited medical infrastructure, and high-altitude environments.

Background and Problem Solved

The original patent disclosed a synthetic pDNA vaccine against COVID-19, but it did not address the unique challenges and requirements of specific environments. This inventive concept solves the problem of inadequate vaccine administration and protection in these environments, ensuring effective vaccination and minimizing risks.

Detailed Description of the Inventive Concept

The inventive concept comprises systems, methods, and kits for administering synthetic pDNA vaccines against COVID-19 in specialized environments. These include secure storage units, controlled environments, portable vaccination units, remote monitoring systems, and supplemental oxygen provision. The inventive concept integrates the original vaccine design with tailored solutions for each environment, ensuring safe and effective vaccination.

Novelty and Inventive Step

The new claims introduce novel combinations of vaccine administration and environmental adaptations, providing a non-obvious solution to the problem of vaccine protection in specialized environments. The inventive concept's unique integration of vaccine design and environmental considerations sets it apart from the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include varying vaccine formulations, adaptable storage and administration systems, and customized training programs for healthcare professionals. Variations may also include integrating the vaccine with existing infrastructure, such as incorporating the vaccine into existing emergency response systems or high-security facilities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries such as biotechnology, healthcare, and emergency response. Target markets include high-security facilities, disaster relief organizations, and areas with limited medical infrastructure. The inventive concept also has potential applications in high-altitude environments, such as mountainous regions or aerospace industries.

CPC Classifications

SectionClassGroup
A A61 A61K39/215
A A61 A61K9/0019
A A61 A61P31/14
C C07 C07K14/005
A A61 A61K2039/53
A A61 A61K2039/54
A A61 A61K2039/545
C C12 C12N2770/20022
C C12 C12N2770/20034
C C12 C12N2770/20071

Original Patent Information

Patent NumberUS 11,857,621
TitleSynthetic pDNA vaccines against COVID-19
Assignee(s)Imam Abdulrahman Bin Faisal University